Lingo does not create any supply challenges to Abbott’s diabetes technology. Abbott will always prioritise the manufacturing of CGMs for diabetes patients.
Abbott has invested hundreds of millions of dollars into high-speed, automated manufacturing for our FreeStyle Libre portfolio – and recently announced a new manufacturing facility in Ireland.